desk
Share
News Topical, Digital Desk : Dr. Reddy's Laboratories has made a major investment of Rs 565 crore in its Russia-based subsidiary DRL Russia. In return for this investment, the company will receive 45.19 percent equity stake in DRL Russia. The company said in the information given to the exchange, "The company has invested Rs 565.40 crore in step-down wholly-owned subsidiary company DRL Russia. In return for this investment, Dr. Reddy's has received 45.19 percent equity stake in DRL Russia." The company's board had approved fund infusion of up to Rs 600 crore as equity investment in DRL Russia. Now the company has implemented it by investing an amount of Rs 565 crore.
This investment has been made with the aim of meeting the working capital requirements of DRL Russia. DRL Russia's turnover in FY 2025 was Rs 2347 crore. The company has clarified that this investment is a related party transaction as DRL Russia is a step-down wholly-owned subsidiary of the company. However, apart from this, the promoter, promoter group or other companies of the group have no stake or interest in it.
About DRL Russia DRL Russia is a pharmaceutical company registered in Russia, which distributes pharmaceutical drugs there. This step is considered to be an important initiative towards further strengthening Dr. Reddy's presence in international markets. Dr Reddy's stock closed at Rs 1,277.10 with a gain of 0.97 per cent on Friday. In the last one year, the company's stock has seen a decline of 1,277.10 percent.
Read More: New IPO: Preparing for a big IPO, Amagi Media Labs filed draft papers with SEBI
--Advertisement--
